Gillian Woollett, MA, DPhil: Policy and Biosimilars
Gillian Woollett, MA, DPhil, senior vice president of Avalere, discusses policy and biosimilars in the United States.
Transcript:
Are there policy changes that would make the United States a better market for biosimilars?
Definitely we need policy changes, but how quickly we can implement what needs legislation, what needs regulations…all of those are delays, so I think what it comes down to is people understanding better what biosimilars offer; that as an economic matter they are essentially generics, and realizing because they’re approved by the FDA they are of the same quality and will have the same clinical outcomes as their reference. There are questions being raised that make it very, very difficult for biosimilars to penetrate. Plus, it takes a significant investment—about $500 million, a hundred times a generic—to get them to market. So, there needs to be a return on investment and yet, they’re being treated like brands, expected to be cheaper but costing more to produce. And so it’s a serious uphill battle.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
BioRationality: FDA Launches a New Opportunity to Remove Redundant Trials of Biosimilars
November 6th 2023The FDA introduced a plan to improve clinical trials, including a provision to possibly eliminate clinical efficacy testing for biologic products, which evidence has suggested may not be necessary, according to Sarfaraz K. Niazi, PhD.
